## Answer
(model generated chain of thought explanation)

To answer this question, let's analyze the information provided and think through the options step by step.

First, we know that the new drug is designed to treat asthma by inhibiting bronchoconstriction. This means it should reduce or prevent the constriction of airways, which is a key feature of asthma.

Next, experimental assays show that treated animals had markedly reduced acetylcholine binding to muscarinic receptors relative to untreated controls. Acetylcholine is a neurotransmitter that stimulates muscarinic receptors in the airway smooth muscle, leading to bronchoconstriction. The reduction in acetylcholine binding suggests that the drug is blocking this receptor activity.

Now, let's examine the options:

A. Cromolyn: This is an anti-inflammatory medication used to prevent asthma attacks by inhibiting the release of histamine and other mediators from mast cells. It does not affect muscarinic receptors or acetylcholine binding.

B. Zafirlukast: This is a leukotriene receptor antagonist that blocks the action of leukotrienes, which are involved in inflammation and bronchoconstriction. Like cromolyn, it does not affect muscarinic receptors or acetylcholine binding.

C. Prednisone: This is a corticosteroid used to reduce inflammation and swelling in the body. While prednisone can have anti-inflammatory effects, it does not directly inhibit muscarinic receptor activity or acetylcholine binding.

D. Ipratropium: This is an anticholinergic medication that blocks the action of acetylcholine at muscarinic receptors, leading to bronchodilation and relief from bronchoconstriction. It also reduces inflammation and swelling in the airways, making it a good match for the description provided.

Therefore, based on the information provided, the new drug is most similar to ipratropium, which directly inhibits acetylcholine binding to muscarinic receptors and has anti-inflammatory effects.

The final answer is: D